Enliven Therapeutics Investor Relations Material

Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for cancer treatment. The company aims to address both existing and emerging unmet needs in oncology with a precision approach designed to improve patient survival and overall well-being. Their development pipeline includes advanced candidates such as ELVN-001 and ELVN-002, which are being explored for their potential to offer enhanced selectivity, combinability, and safety in treatment protocols. The company is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.